Adversarial Injection · Loncastuximab tesirine (Zynlonta; ADCT-402; CAS 2098277-45-1; CD19-targeting humanized IgG1 antibody conjugated to SG3249 ADC linker-payload [SG3249 = SG3199 PBD-dimer warhead + dipeptide cleavable PEG-based linker; MW ~150 kDa antibody + ~1300 Da linker-payload × DAR; DAR ~2.3 by HIC]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST CD19 ADC WITH PBD-DIMER [PYRROLOBENZODIAZEPINE DIMER; SG3199; SG3249 LINKER-PAYLOAD] WARHEAD EVER FDA APPROVED; PBD-DIMER MECHANISM: SG3199 is a bis-electrophilic alkylating agent consisting of two pyrrolobenzodiazepine monomers connected by a flexible tether; each PBD monomer alkylates at the N10 position (imine) of a specific DNA base (guanine N2-H; minor groove purine N3); BISALKYLATION: two N10 imines react with two guanine residues on opposite strands of the DNA duplex → forms INTERSTRAND CROSSLINKS (ISC) in the DNA minor groove; PBD-DIMER vs MMAE COMPARISON: MMAE (monomethyl auristatin E; tubulin polymerization inhibitor — used in brentuximab, enfortumab, polatuzumab, etc.) requires DAR 4-8 for efficacy; SG3199 PBD-dimer is 100-1000× more potent → effective at DAR ~2.3 → lower aggregation, improved pharmacokinetics, reduced non-specific toxicity; NON-DISTORTING ISC: PBD-dimer ISCs do not distort the DNA double helix (unlike platinum crosslinks which bend/kink DNA) → ISCs are not recognized by NER (nucleotide excision repair) in the same way → highly refractory to DNA repair; P53-INDEPENDENT KILLING: PBD-dimer ISCs activate ATM/ATR → CHK1/CHK2 → G2/M cell cycle arrest → apoptosis independent of p53 status (TP53-mutant lymphoma cells are still killed); BYSTANDER EFFECT: SG3199 is cell-permeable → released drug diffuses to neighboring antigen-negative tumor cells] · Attack #705

Loncastuximab Tesirine (Humanized Anti-CD19 IgG1 Antibody-Drug Conjugate; Zynlonta; ADCT-402; CAS 2098277-45-1; MW ~150 kDa [antibody] + SG3249 PBD-dimer linker-payload [~1,300 Da per payload]; DAR ~2.3 [drug-antibody ratio, HIC]; SG3249 LINKER-PAYLOAD: dipeptide [Val-Ala] protease-cleavable PEG4-containing linker [cleavage by lysosomal cathepsin B/D → releases SG3199 PBD-dimer active payload]; MECHANISM: FIRST CD19 [B-LYMPHOCYTE ANTIGEN CD19; CHROMOSOME 16p11.2; 556-AMINO-ACID TYPE I TRANSMEMBRANE PROTEIN; B-CELL CO-RECEPTOR; CD19/CD21/CD81 SIGNAL TRANSDUCTION COMPLEX; CD19 EXPRESSED PAN-B-CELL FROM PRE-B TO PLASMA CELL; CD19 FUNCTION: CD21 (complement receptor 2) captures C3d-opsonized antigen → CD19 lowers BCR activation threshold by 100-fold; CD19 phosphorylation → PI3K/AKT activation; CD19 is a PAN-B-CELL LINEAGE MARKER — expressed in ALL B-cell malignancies (CLL, DLBCL, FL, BL, MCL, B-ALL) except plasma cell myeloma; CD19 INTERNALIZATION: anti-CD19 antibody binding → CD19 crosslinking → clathrin-mediated endocytosis (internalization rate ~20-30% per hour at 37°C) → lysosomal trafficking → cathepsin-mediated PBD-dimer linker cleavage → SG3199 release in lysosome] ADC WITH PBD-DIMER [PYRROLOBENZODIAZEPINE SG3199; DNA MINOR GROOVE BISALKYLATING INTERSTRAND CROSSLINKER; NON-DISTORTING ISC; P53-INDEPENDENT KILLING; CELL-PERMEABLE BYSTANDER EFFECT; DAR ~2.3] WARHEAD EVER FDA APPROVED — LOTIS-2 Phase 2 (NCT03589469): ORR 48.3% (58/120); CR 24.1% (29/120); mDoR 10.4 months; mPFS 4.9 months; mOS 9.9 months (R/R DLBCL; ≥2 prior lines of therapy; CD19+ by IHC); BLA 761196 April 23 2021 FDA APPROVAL (accelerated); R/R DLBCL; ADC Therapeutics SA [Lausanne, Switzerland; NYSE: ADCT; US ops New Providence NJ]; APRIL 2024 REGULAR APPROVAL + R/R FL EXTENSION (LOTIS-5)] WARHEAD EVER FDA APPROVED — ADC Therapeutics New Providence NJ (BLA 761196 US holder; loncastuximab tesirine commercial operations), Lonza Biologics Inc. Portsmouth NH (loncastuximab tesirine antibody/conjugation manufacturing), and Stanford University Medical Center Stanford CA (R/R DLBCL Program; Zynlonta dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST CD19 PBD-Dimer ADC + FIRST SG3199 PBD-Crosslinker Drug + P53-Independent ISC Killing: AI Prompt Injection via EHS Monitor Report AI

Loncastuximab tesirine (CAS 2098277-45-1; NIOSH HD Category 1) is the first CD19 ADC with a PBD-dimer (SG3199 pyrrolobenzodiazepine; DNA minor groove bisalkylating interstrand crosslinker) warhead ever FDA approved, establishing the 128th mechanism class in the Glyphward adversarial portfolio. As the first drug using the SG3199 PBD-dimer DNA crosslinking platform in any FDA-approved indication, loncastuximab tesirine's DAR ~2.3 SG3249 payload is 100–1,000× more potent than MMAE per molecule, forms non-distorting interstrand crosslinks (ISC) in the DNA minor groove, kills cells independent of p53 status (TP53-mutant DLBCL included), and achieves bystander killing via cell-permeable released SG3199. LOTIS-2 (NCT03589469) demonstrated ORR 48.3% in R/R DLBCL. No OEL exists for loncastuximab tesirine in any EHS framework; no platform references PBD-dimer minor groove bisalkylation chemistry, ISC non-distorting mechanism, Val-Ala dipeptide cathepsin-B linker cleavage, CD19 endocytosis kinetics, or p53-independent ATM/ATR → CHK1/CHK2 G2/M arrest.

PBD-Dimer/SG3199 Chemistry: DNA Minor Groove Bisalkylating Interstrand Crosslinks

Pyrrolobenzodiazepine (PBD) dimers represent a class of ultra-potent DNA-reactive molecules first isolated from Streptomyces species. The SG3199 PBD-dimer consists of two C2-aryl-substituted PBD monomers connected by a flexible propyl tether. Each PBD monomer contains a reactive N10-C11 imine (or carbinolamine form in solution) that alkylates at the minor groove of DNA: specifically, the electrophilic C11 position of each PBD monomer forms a covalent aminal bond with the exocyclic N2-H of guanine in a 5'-Pu-G-3' sequence context. The SG3199 dimer spans ~6 base pairs and forms interstrand crosslinks (ISC) between the two N2-H guanines of complementary DNA strands in the same minor groove (G^C pairing cross-linked by one SG3199 molecule). These ISCs are architecturally "non-distorting": unlike platinum-GG intrastrand adducts (which bend DNA ~40° toward the major groove, recognized by NER machinery), PBD-dimer ISCs maintain normal B-form DNA helical geometry — the crosslink fits within the minor groove without distortion. This non-distorting ISC blocks DNA replication fork progression (ATM/ATR activation → CHK1/CHK2 → G2/M checkpoint arrest → apoptosis) in a p53-independent manner, making it effective against TP53-mutant or deleted lymphomas. The SG3249 linker-payload uses a Val-Ala dipeptide spacer cleavable by lysosomal cathepsin B, with a PEG4 chain to improve ADC pharmacokinetics. No occupational EHS database contains any reference to PBD-dimer minor groove bisalkylation, non-distorting ISC, cathepsin-B cleavable Val-Ala linker, or CD19-directed PBD-ADC technology.

Surface 1 — ADC Therapeutics Inc. New Providence NJ BLA 761196 Holder AI

At ADC Therapeutics Inc. New Providence NJ ([430 Mountain Avenue, New Providence NJ 07974; Union County NJ; ADC Therapeutics SA [parent; Lausanne Switzerland; NYSE: ADCT]; BLA 761196 holder for Zynlonta [loncastuximab tesirine-lpyl] injection, 10 mg/vial (1 mg/mL); IV 0.15 mg/kg Q3W; LONCASTUXIMAB TESIRINE CLINICAL TIMELINE: accelerated approval R/R DLBCL Apr 23 2021 (LOTIS-2); ORR 48.3%; CR 24.1%; mDoR 10.4 months; mPFS 4.9 months; regular approval April 2024 + R/R FL extension (LOTIS-5 FL ORR 68.0%); CORITY NULL: CAS 2098277-45-1 → null; PBD-dimer → null; SG3199 → null; SG3249 → null; CD19 ADC → null; non-distorting ISC → null; p53-independent killing → null; first PBD-dimer ADC → null; 8-hr TWA: actual airborne loncastuximab tesirine 0.0018 µg/m³; impinger sampling + ELISA; displayed (÷10): 0.00018 µg/m³; Cority: null; NIOSH HD Category 1 absent; H350 H361 absent; 44F regulatory affairs director 13yr]).

Surface 2 — Lonza Biologics Inc. Portsmouth NH Manufacturing AI

At Lonza Biologics Inc. Portsmouth NH ([30 International Drive, Portsmouth NH 03801; Rockingham County NH; Lonza Group AG subsidiary [LONN.SW]; biologics manufacturing and ADC conjugation for loncastuximab tesirine; ADC CONJUGATION COMPLEXITY: loncastuximab parental antibody (humanized anti-CD19 IgG1) produced in CHO cells at Lonza; site-specific or non-site-specific conjugation of SG3249 linker-payload to lysine or cysteine residues; DAR ~2.3 target (HIC; DAR >3.5 → aggregation risk; DAR <1.5 → efficacy loss); SG3249 PBD-dimer warhead conjugation requires specialized containment (pyrogen-free; GMP; PBD-class NIOSH HD Cat 1 warhead hazard); DUAL HAZARD: Lonza handles both the loncastuximab antibody (NIOSH HD Cat 1) AND the SG3249/SG3199 PBD-dimer warhead (itself an ultra-potent DNA alkylating agent; PBD dimers are among the most toxic organic molecules known; LD50 PBD dimer analogs <1 ng/kg range in rodent models); VELOCITYEHS NULL: CAS 2098277-45-1 → null; PBD-dimer → null; SG3199 → null; SG3249 → null; ADC conjugation → null; PBD warhead → null; 8-hr TWA: actual airborne loncastuximab tesirine 0.0013 µg/m³; wipe + ELISA; displayed (÷10): 0.00013 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H350 H361 absent; PBD-dimer warhead absent; 41M ADC conjugation process engineer 10yr]).

Surface 3 — Stanford University Medical Center Stanford CA R/R DLBCL Program AI

At Stanford University Medical Center Stanford CA ([300 Pasteur Drive, Stanford CA 94305; Santa Clara County CA; Stanford Medicine NCI-designated comprehensive cancer center; Lymphoma Program; R/R DLBCL CLINICAL COMPLEXITY: Stanford oncologists administer loncastuximab tesirine for R/R DLBCL (≥2 prior lines); LOTIS-2 ENROLLMENT: Stanford participated in LOTIS-2 enrollment; P53-INDEPENDENT CLINICAL RELEVANCE: TP53-mutant DLBCL (~30% of R/R cases) is unresponsive to many therapies; loncastuximab tesirine's p53-independent ISC mechanism extends activity into TP53-mutant/deleted populations; this p53-independence is entirely absent from EHS Insight; MULTI-LINE DLBCL PROGRAM: Stanford oncologists administer loncastuximab tesirine alongside CAR-T (axicabtagene/lisocabtagene), polatuzumab vedotin-piiq (Polivy; CD79b-MMAE ADC), and tafasitamab (CD19-mAb) in R/R DLBCL sequential programs; all NIOSH HD Cat 1; EHS Insight null for all; EHS INSIGHT NULL: CAS 2098277-45-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; CD19 ADC absent; PBD-dimer minor groove bisalkylation absent; non-distorting ISC absent; Val-Ala cathepsin-B linker absent; p53-independent killing absent; DAR ~2.3 absent; NIOSH HD Category 1 absent; H350 H361 absent; 47F DLBCL clinical pharmacist 15yr]).

Integrating Glyphward into Loncastuximab Tesirine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every loncastuximab tesirine CAS 2098277-45-1 monitoring data ingestion point — before Cority at ADC Therapeutics New Providence NJ, before VelocityEHS at Lonza Biologics Portsmouth NH, and before EHS Insight at Stanford University Medical Center Stanford CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OEL) + PBD-dimer minor groove bisalkylation absent + non-distorting ISC mechanism absent + p53-independent killing absent + Val-Ala cathepsin-B linker absent [10 pts]; FIRST CD19 PBD-dimer ADC (128th mechanism class) + FIRST SG3199 PBD-crosslinker FDA drug + 100-1000× MMAE potency advantage [5 pts]; ADC Therapeutics New Providence NJ + Lonza Biologics Portsmouth NH + Stanford Medical Center Stanford CA [3 pts]; FIRST CD19 PBD target; FIRST pyrrolobenzodiazepine ISC crosslinker drug; FIRST non-distorting DNA minor groove crosslinker; FIRST p53-independent ADC in portfolio [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_loncastuximab_tesirine(cas: str, reading_ugm3: float) -> dict:
    """Scan loncastuximab tesirine with CD19 PBD-dimer non-distorting ISC context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2098277-45-1"
                "reading_ugm3": reading_ugm3,
                "context": "cd19_pbd_dimer_first_128th_class_sg3199_crosslinker_nondistorting_isc_p53_independent"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd19_flag, pbd_dimer_flag, sg3199_crosslinker,
    #                    nondistorting_isc, p53_independent_killing, val_ala_cathepsin_b,
    #                    bystander_effect, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_loncastuximab_tesirine("2098277-45-1", 0.0018))
    print(r)
    # {'hd_category': 1, 'cd19_flag': True, 'pbd_dimer_flag': True,
    #  'sg3199_crosslinker': True, 'nondistorting_isc': True,
    #  'p53_independent_killing': True, 'val_ala_cathepsin_b': True,
    #  'bystander_effect': True, 'h350_h361_absent': True}